Status: Not yet recruiting
Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
This feasibility trial studies the efficacy of administering iberdomide (CC-220) as a priming agent prior to leukapheresis in patients with relapsed/refractory multiple myeloma (RRMM) who are already planned for standard-of-care CAR-T therapy. Giving iberdomide before CAR-T may improve T cell fitness which may improve CAR-T expansion kinetics and response after infusion.
Participants needed: 22
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Shambavi RichardUpdated: Jul 27, 2026Locations: 1
Eligibility criteria
Subject is ≥18 years of age at the time of signing the informed consent form (IC... [+11]
Subjects with monoclonal gammopathy of undetermined significance (MGUS), smolder... [+31]